Company Description

Tegmine targets glycoproteins, which are a hallmark of numerous solid cancers and drive aggressive disease. The company has engineered a system to generate revolutionary new antibody-based therapies for cancer which dramatically increase efficacy while reducing toxic side effects. Their proprietary TegMiner™ platform enables the discovery of unique cancer epitopes and allows them to develop these life-changing new antibodies for patients with unmet needs.